Cliff Asness's HAE Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 3.16 M shares of Haemonetics Corporation (HAE) worth $253.52 M, representing 0.13% of the portfolio. First purchased in 2012-Q4, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in HAE, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 1.68 M shares. Largest reduction occurred in Q2 2019, reducing 411,879 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +1.03 M | Add 48.58% | 3.16 M | $80.15 |
| Q3 2025 | +1.68 M | Add 372.82% | 2.13 M | $48.29 |
| Q2 2025 | +275,683 | Add 157.93% | 450,248 | $74.16 |
| Q1 2025 | +149,325 | Add 591.62% | 174,565 | $62.62 |
| Q4 2024 | +11,240 | Add 80.29% | 25,240 | $77.27 |
| Q3 2024 | -69,988 | Reduce 83.33% | 14,000 | $80.38 |
| Q2 2024 | -44,787 | Reduce 34.78% | 83,988 | $82.73 |
| Q1 2024 | -10,143 | Reduce 7.30% | 128,775 | $84.38 |
| Q4 2023 | -57,579 | Reduce 29.30% | 138,918 | $85.51 |
| Q3 2023 | -10,584 | Reduce 5.11% | 196,497 | $89.58 |
| Q2 2023 | +57,790 | Add 38.71% | 207,081 | $85.14 |
| Q1 2023 | +90,092 | Add 152.19% | 149,291 | $82.17 |
| Q4 2022 | +16,916 | Add 40.01% | 59,199 | $78.35 |
| Q3 2022 | +34,849 | Add 468.78% | 42,283 | $74.03 |
| Q2 2022 | -18,279 | Reduce 71.09% | 7,434 | $64.70 |
| Q1 2022 | +18,704 | Add 266.86% | 25,713 | $62.46 |
| Q4 2021 | -62,216 | Reduce 89.88% | 7,009 | $53.07 |
| Q3 2021 | -21,870 | Reduce 24.01% | 69,225 | $70.60 |
| Q2 2021 | +56,287 | Add 161.71% | 91,095 | $66.07 |
| Q1 2021 | -22,706 | Reduce 39.48% | 34,808 | $111.01 |
| Q4 2020 | -23,527 | Reduce 29.03% | 57,514 | $118.56 |
| Q3 2020 | +22,640 | Add 38.77% | 81,041 | $86.10 |
| Q2 2020 | +14,964 | Add 34.45% | 58,401 | $87.58 |
| Q1 2020 | -108,264 | Reduce 71.37% | 43,437 | $99.66 |
| Q4 2019 | -147,400 | Reduce 49.28% | 151,701 | $114.90 |
| Q3 2019 | -372,530 | Reduce 55.47% | 299,101 | $126.14 |
| Q2 2019 | -411,879 | Reduce 38.01% | 671,631 | $119.35 |
| Q1 2019 | +215,054 | Add 24.76% | 1.08 M | $87.48 |
| Q4 2018 | +420,673 | Add 93.95% | 868,456 | $100.05 |
| Q3 2018 | +270,157 | Add 152.09% | 447,783 | $114.58 |
| Q2 2018 | +82,213 | Add 86.17% | 177,626 | $89.68 |
| Q1 2018 | +84,057 | Add 740.20% | 95,413 | $73.17 |
| Q4 2017 | +6,592 | Add 138.37% | 11,356 | $58.12 |
| Q3 2017 | +4,764 | New Buy | 4,764 | $44.92 |
| Q2 2017 | -8,202 | Sold Out | 0 | $0.00 |
| Q4 2016 | -37,687 | Reduce 82.13% | 8,202 | $40.23 |
| Q3 2016 | +2,530 | Add 5.84% | 45,889 | $36.20 |
| Q2 2016 | +43,359 | New Buy | 43,359 | $28.99 |
| Q4 2015 | -8,397 | Sold Out | 0 | $0.00 |
| Q3 2015 | -6,222 | Reduce 42.56% | 8,397 | $32.27 |
| Q2 2015 | +14,619 | New Buy | 14,619 | $41.38 |
| Q3 2013 | -6,200 | Sold Out | 0 | $0.00 |
| Q2 2013 | +6,200 | Add 0.00% | 6,200 | $41.29 |
| Q4 2012 | +6,200 | Add 0.00% | 6,200 | $40.81 |
Cliff Asness's Haemonetics Corporation Investment FAQs
Cliff Asness first purchased Haemonetics Corporation (HAE) in Q4 2012, acquiring 6,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Haemonetics Corporation (HAE) for 46 quarters since Q4 2012.
Cliff Asness's largest addition to Haemonetics Corporation (HAE) was in Q3 2025, adding 2,128,878 shares worth $102.81 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 3,163,104 shares of Haemonetics Corporation (HAE), valued at approximately $253.52 M.
As of the Q4 2025 filing, Haemonetics Corporation (HAE) represents approximately 0.13% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Haemonetics Corporation (HAE) was 3,163,104 shares, as reported at the end of Q4 2025.